Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12612000709842
ACTRN12612000709842
Completed
Phase 1

A randomised controlled trial to evaluate the immune response to an adjuvanted 2012 seasonal trivalent inactivated influenza vaccine in adults

Vaxine Pty Ltd0 sites200 target enrollmentJuly 3, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPrevention of influenza infectionInfection - Other infectious diseasesPublic Health - Other public health

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Prevention of influenza infection
Sponsor
Vaxine Pty Ltd
Enrollment
200
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 3, 2012
End Date
December 31, 2014
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Male or female
  • •Age 18 years or over
  • •Able to provide written informed consent
  • •Willing and able to comply with the protocol for the duration of the study.

Exclusion Criteria

  • •History of vaccination with the 2012 seasonal influenza vaccine
  • •History of serious vaccine or egg allergy
  • •Women of childbearing potential, unless using a reliable and appropriate contraceptive method, specifically oral contraceptive pill, IUD or mechanical barrier device.
  • •Pregnant or lactating women.
  • •Receipt of another investigational agent within 14 days preceding initiation of treatment.
  • •Any other serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Trial to study the effect of Curvic® in vaccinated population for COVID-19Vaccinated for COVID-19Infections and InfestationsCOVID-19 (SARS-CoV-2 infection)
ISRCTN26285740Shreepad Shree Vallabh SSV Phytopharmaceuticals50
Completed
Phase 3
A prospective randomized controlled trial of immunoglobulin plus prednisolone for Kawasaki disease patients with high risk for coronary abnormalitiesKawasaki disease
JPRN-UMIN000009524agoya University Graduate School of Medicine, Department of Pediatrics240
Completed
Phase 3
Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki diseaseKawasaki disease
JPRN-UMIN000000940Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease (RAISE) Study Group392
Active, not recruiting
Not Applicable
Immunogenicity and safety study of GSK Biologicals’ Infanrix-IPV+Hib™ vaccine.Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases.Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2011-005868-25-Outside-EU/EEAGlaxoSmithKline Biologicals985
Active, not recruiting
Not Applicable
Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ inactivated polio vaccine (Poliorix) in infants.Primary immunisation of healthy infants in the first year of life against poliomyelitisTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2011-003167-30-Outside-EU/EEAGlaxoSmithKline Biologicals1,101